SynChem boosts Formosa’s presence
Formosa Laboratories, a Taiwan-based API supplier and CDMO, has completed the acquisition of SynChem, a contract research laboratory located in suburban Chicago. SynChem will now operate as SynChem-Formosa, with Dr W. Paul Mar continuing as CEO. Terms were not disclosed.
Dr Cheng, chairman and president of Formosa, particularly noted SynChem's track record in areas such as ADC payloads and linkers. Added to Formosa’s capabilities in scale-up, commercial GMP production, bio-conjugation and injectable fill-finish operations, he said, “we are now poised to offer comprehensive, fully GMP-compliant CDMO services to our clients across the US and internationally.”
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
